MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$363,308K
Free Cash flow
-$82,176K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net proceeds from the issuance o...
Proceeds from maturities of mark...
Proceeds from stock option exerc...
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2025-12-31
2024-12-31
2023-12-31
2022-12-31
License revenue
-
-
-
0
Research and development
-
70,112
63,497
39,617
General and administrative
-
31,759
39,061
22,412
Total operating expenses
-
101,871
102,558
62,029
Loss from operations
-
-101,871
-102,558
-62,029
Interest income
-
13,289
12,901
2,110
Other expense, net
-
-11
-314
-68
Total other income, net
-
13,278
12,587
2,042
Loss before income taxes
-
-88,593
-89,971
-59,987
Income tax expense
-
260
239
358
Net loss
-96,207
-88,853
-90,210
-60,345
Stock-based compensation expense
13,398
15,627
25,536
10,768
Depreciation and amortization expense
90
319
292
484
Net accretion on marketable securities
-58
-2,090
-5,029
81
Change in deferred taxes and uncertain tax positions
-511
-23
-141
-392
Amortization of operating lease assets
411
577
589
548
Prepaid expenses and other current assets
1,181
-47
1,921
1,121
Other assets
-
-
-
0
Accrued interest, net of interest received
-1,173
-1,012
-
-
Accounts payable
-512
-367
1,149
-722
Accrued expenses and other current liabilities
629
4,244
2,729
1,416
Operating lease liabilities
-430
-555
-666
-610
Deferred rent
-
-
-
0
Net cash used in operating activities
-82,176
-70,016
-67,390
-49,109
Purchase of property and equipment
0
42
52
275
Purchase of investments
-
-
275,781
139,731
Purchase of marketable securities
405,043
169,942
-
-
Proceeds from maturities of marketable securities
107,000
157,574
237,846
117,734
Net cash used in investing activities
-298,043
-12,410
-37,987
-22,272
Net proceeds from the issuance of common stock
706,388
0
41,611
24,993
Net proceeds from the issuance of common stock and pre-funded warrants
0
162,312
0
61,145
Payment of deferred offering costs
235
388
344
401
Proceeds from the issuance of common stock under employee stock purchase plan
-
-
410
243
Net proceeds from initial public offering
-
-
-
0
Proceeds from notes receivable
-
-
-
0
Payment of loans payable
-
-
-
0
Proceeds from stock option exercises
36,845
1,448
274
0
Proceeds from the issuance of common stock under employee stock purchase plan
513
623
0
81,115
Net cash provided by financing activities
743,511
163,995
41,951
167,095
Effect of exchange rate changes on cash and cash equivalents
16
-56
117
-178
Net increase in cash and cash equivalents
363,308
81,513
-63,309
95,536
Cash and cash equivalents at beginning of period
161,439
79,926
143,235
47,699
Cash and cash equivalents at end of period
524,747
161,439
79,926
143,235
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
the issuance of...
$706,388K
Proceeds from stock
option exercises
$36,845K
(2444.54%↑ Y/Y)
Proceeds from the
issuance of common stock...
$513K
(-17.66%↓ Y/Y)
Net cash provided by
financing activities
$743,511K
(353.37%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$16K
(128.57%↑ Y/Y)
Canceled cashflow
$235K
Net increase in cash
and cash...
$363,308K
(345.71%↑ Y/Y)
Canceled cashflow
$380,219K
Payment of deferred
offering costs
$235K
(-39.43%↓ Y/Y)
Proceeds from maturities
of marketable...
$107,000K
(-32.10%↓ Y/Y)
Stock-based compensation
expense
$13,398K
(-14.26%↓ Y/Y)
Accrued interest, net of
interest received
-$1,173K
(-15.91%↓ Y/Y)
Accrued expenses and
other current...
$629K
(-85.18%↓ Y/Y)
Change in deferred
taxes and uncertain...
-$511K
(-2121.74%↓ Y/Y)
Amortization of operating
lease assets
$411K
(-28.77%↓ Y/Y)
Depreciation and
amortization expense
$90K
(-71.79%↓ Y/Y)
Net cash used in
investing activities
-$298,043K
(-2301.64%↓ Y/Y)
Net cash used in
operating activities
-$82,176K
(-17.37%↓ Y/Y)
Canceled cashflow
$107,000K
Canceled cashflow
$16,212K
Purchase of marketable
securities
$405,043K
(138.34%↑ Y/Y)
Net loss
-$96,207K
(-8.28%↓ Y/Y)
Prepaid expenses and
other current assets
$1,181K
(2612.77%↑ Y/Y)
Accounts payable
-$512K
(-39.51%↓ Y/Y)
Operating lease
liabilities
-$430K
(22.52%↑ Y/Y)
Net accretion on
marketable securities
-$58K
(97.22%↑ Y/Y)
Buy us a coffee
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)